New autism drug shows promise in preclinical study
Research concerning autism spectrum disorder (ASD) has seen its fair share of controversy over the years, but as researchers relentlessly pursue the underlying causes of this developmental disorder, scientific consensus and public awareness grow. Adding to the exponential growth of data for ASD, a group of investigators led by researchers at Sanford Burnham Prebys Medical Discovery Institute has just released findings from a successful test of a possible new drug in a mouse model of an autism disorder. The candidate drug, called NitroSynapsin, largely corrected electrical, behavioral, and brain abnormalities in the mice.
Findings from the new study were published today in Nature Communications in an article entitled “NitroSynapsin Therapy for a Mouse MEF2C Haploinsufficiency Model of Human Autism.” NitroSynapsin is intended to restore an electrical signaling imbalance in the brain found in virtually all forms of ASD.
- Read Full Item
- 14th November 2017
- Genetic Engineering and Biotechnology News